


Conditional Request For Constructive Assistance

Applicant has amended the claims of this application so that they are proper, definitive, and define a novel method which is also unobvious. If, for any reason this application is not believed to be in full condition for allowance, applicant respectfully requests the constructive assistance and suggestions of the Examiner pursuant to M.P.E.P. 706.03(d) and 707.07(j) in order that the undersigned can place this application in allowable condition as soon as possible and without the need for further proceedings.

Very respectfully,



Mark Zamoyski
Applicant Pro Se
988 Foothill Drive, San Jose, CA 95123
Tel: 408-365-1170 Fax: 408-365-9898

Certificate of Mailing: Deposited with the U.S. Postal Service as express mail in an envelope addressed to: "MAIL STOP NON-FEE AMENDMENTS, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450"

Express Mail Label #

EQ169790805US

Date Mailed:

7/26/05

EXHIBIT A: Comparative PSR Potency and Safety for Representative Trichothecenes

MOLECULE DESCRIPTIONHuman Lung Dose/Safety

ID 50
(ng/ml)

LD 50
(in mg/kg BW)

Type A	Molecular Formula	Molec. Mass	Mit Pt (°C)	CAS Number	HEp2 /HSV2	IV	IP	Lung Dose 3X ID50 (in ng.)	LD 50 (in ng.)	Times Safer
T-2 Toxin	C24 H34 O9	466	151	21259-20-1	1.6	4.2	5.2	5760	294000000	51,042
DAS (Diacetoxyscirpenol)	C19 H26 O7	366	162	2270-40-8	2.3	12	15	8280	840000000	101,449
NEOS (Neosolaniol)	C19 H26 O8	382	171	36519-25-2	52		14.5	187200	1015000000	5,422

Type B

DON (Deoxynivalenol)	C15 H20 O6	296	151	51481-10-8	94	7.3	70	338400	4900000000	14,480
NIV (Nivalenol)	C15 H20 O7	312	222	23282-20-4	50	3.4	7.4	180000	511000000	2,839
FusX (Fusarenon - X)	C17 H22 O8	354	91	23255-69-8	26		3.4	93600	238000000	2,543

Type C

Crotocin					250			900000		
----------	--	--	--	--	-----	--	--	--------	--	--

Macrocyclic

Satratoxin G	C29 H36 O10				1.5			5400	70000000	13,889
Satratoxin H	C29 H36 O9	528	162		1.4	1	1	5040	70000000	29,167
Roridin A	C29 H40 O9	532	198		1	1.5	0.5	3600	105000000	
Verrucaric A	C27 H34 O9	502	360		41			147600		
Baccharinoid B-4					9			32400		
Baccharinoid B-5										

Notes & Abbreviations:

Cell line origin: HEp2 = epidermoid carcinoma

Administration Route: IV = intravenous, IP = intraperitoneal

ID 50 for cells: concentration required for 50% protein synthesis inhibition in cultured human epidermoid cell lines - HSV protein synthesis inhibition model used

Administration Route: IV = intravenous, IP = intraperitoneal

LD 50 based on mouse models

Human Lung Dose/Safety: 3 times ID50 used for ~ complete protein synthesis restriction (PSR), 1200 grams = average human lung

LD50 based on avg. 70 KG human, IV LD 50 used when available, otherwise IP LD 50 used

Times safer = LD 50 in ng + 3X ID 50 lung dose in ng. (in animal models 5 X safer = no mortality)